Código QR

Denosumab Treatment Does Not Halt Progression of Bone Lesions in Multicentric Carpotarsal Osteolysis Syndrome

ABSTRACT Here we report the use of denosumab, a monoclonal antibody against receptor activator of nuclear factor κB ligand (RANKL), as monotherapy for multicentric carpotarsal osteolysis syndrome (MCTO) in an 11.5‐year‐old male with a heterozygous missense mutation in MAFB (c.206C>T; p.Ser69Leu). We...

Descrición completa

Gardado en:
Detalles Bibliográficos
Principais autores: Melissa A. Lerman, Michael Francavilla, Lindsay Waqar‐Cowles, Michael A. Levine
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2023-05-01
Series:JBMR Plus
Assuntos:
Acceso en liña:https://doi.org/10.1002/jbm4.10729
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!